Baclofen vs placebo
- no estimate extracted1 study · 31 participantsVery low
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Summary of findings table ‐ Baclofen probably leads to lower relapse: return to any drinking at end of treatment compared with placebo (moderate certainty).
It is very uncertain whether summary of findings table ‐ Baclofen changes dropouts at end of treatment compared with acamprosate (very low certainty).
It is very uncertain whether summary of findings table ‐ Baclofen changes dropouts due to adverse events compared with acamprosate (very low certainty).
It is very uncertain whether summary of findings table ‐ Baclofen changes relapse: return to any drinking at end of treatment compared with naltrexone (very low certainty).
It is very uncertain whether summary of findings table ‐ Baclofen changes adverse events: number of participants with ≥ 1 adverse event at end… compared with naltrexone (very low certainty).
It is very uncertain whether summary of findings table ‐ Baclofen changes dropouts at end of treatment compared with naltrexone (very low certainty).
Summary of findings table ‐ Baclofen showed no clear difference in adverse events: number of participants with ≥ 1 adverse event at end… compared with placebo (high certainty).
Summary of findings table ‐ Baclofen showed no clear difference in dropouts at end of treatment compared with placebo (high certainty).
Summary of findings table ‐ Baclofen showed no clear difference in dropouts due to adverse events compared with placebo (high certainty).
It is very uncertain whether summary of findings table ‐ Baclofen changes relapse: return to any drinking at end of treatment compared with acamprosate (very low certainty).